Alzheimer's Risk Gene TREM2 Determines Functional Properties of New Type of Human iPSC-Derived Microglia.

Alzheimer Disease Cell Culture Techniques / methods Cell Differentiation Cells, Cultured Genetic Predisposition to Disease Humans Induced Pluripotent Stem Cells / metabolism Membrane Glycoproteins / genetics Microglia / metabolism Receptors, Immunologic / genetics
Alzheimer’s disease (AD) TREM2 (triggering receptor expressed on myeloid cells) cell culture protocols drug development iPSC (induced pluripotent stem cell) microglia

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 15 10 2020
accepted: 29 12 2020
entrez: 22 2 2021
pubmed: 23 2 2021
medline: 22 6 2021
Statut: epublish

Résumé

Microglia are key in the homeostatic well-being of the brain and microglial dysfunction has been implicated in neurodegenerative disorders such as Alzheimer's disease (AD). Due to the many limitations to study microglia

Identifiants

DOI: 10.3389/fimmu.2020.617860 PMID: 33613545 PMC: PMC7887311
pubmed: 33613545
doi: 10.3389/fimmu.2020.617860
pmc: PMC7887311
doi:

Substances chimiques

Membrane Glycoproteins 0
Receptors, Immunologic 0
TREM2 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

617860

Subventions

Organisme : Medical Research Council
ID : MC_EX_MR/N50192X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L023784/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M024962/1
Pays : United Kingdom

Informations de copyright

Copyright © 2021 Reich, Paris, Ebeling, Dahm, Schweitzer, Reinhardt, Schmucki, Prasad, Köchl, Leist, Cowley, Zhang, Patsch, Gutbier and Britschgi.

Déclaration de conflit d'intérêts

During the course of this study, MR, IP, ND, CS, DR, RS, ME, JZ, CP, SG, and MB are or were full time employees or trainees at Roche and they may additionally hold Roche stock/stock options. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Cell. 2013 Dec 19;155(7):1596-609
pubmed: 24360280
EMBO Rep. 2017 Jul;18(7):1186-1198
pubmed: 28483841
JAMA Neurol. 2015 Aug;72(8):920-7
pubmed: 26076170
BMC Genet. 2020 Sep 9;21(1):101
pubmed: 32907542
J Exp Med. 2020 Sep 7;217(9):
pubmed: 32579671
Stem Cell Reports. 2017 Jun 6;8(6):1727-1742
pubmed: 28591653
Nat Neurosci. 2020 Aug;23(8):927-938
pubmed: 32514138
Trends Neurosci. 2019 Nov;42(11):778-792
pubmed: 31635851
Neuron. 2017 May 17;94(4):759-773.e8
pubmed: 28521131
Am J Pathol. 1997 Jan;150(1):31-41
pubmed: 9006319
Nat Genet. 2013 Dec;45(12):1452-8
pubmed: 24162737
Mol Vis. 2017 Apr 10;23:210-218
pubmed: 28442885
J Neuroimmunol. 2006 Nov;180(1-2):71-87
pubmed: 16996144
EMBO J. 2017 Jul 3;36(13):1837-1853
pubmed: 28559417
Front Immunol. 2019 Sep 04;10:2055
pubmed: 31552022
Science. 2011 Sep 9;333(6048):1456-8
pubmed: 21778362
Cell. 2017 Jun 15;169(7):1276-1290.e17
pubmed: 28602351
Mol Cell Neurosci. 2019 Oct;100:103392
pubmed: 31381983
Nat Neurosci. 2017 May;20(5):753-759
pubmed: 28253233
J Neurosci. 2014 Feb 5;34(6):2231-43
pubmed: 24501362
Nat Rev Neurol. 2018 Nov;14(11):667-675
pubmed: 30266932
PLoS One. 2013 Aug 12;8(8):e71098
pubmed: 23951090
Nat Rev Neurosci. 2016 Apr;17(4):201-7
pubmed: 26911435
Cell. 2018 May 17;173(5):1073-1081
pubmed: 29775591
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Immunity. 2019 Jan 15;50(1):253-271.e6
pubmed: 30471926
Cell Rep. 2019 Apr 23;27(4):1293-1306.e6
pubmed: 31018141
J Neurosci. 2001 Mar 15;21(6):1975-82
pubmed: 11245682
Int J Mol Sci. 2020 Jul 07;21(13):
pubmed: 32645954
J Neurosci. 2020 Feb 26;40(9):1956-1974
pubmed: 31980586
Nat Rev Immunol. 2018 Dec;18(12):759-772
pubmed: 30140051
ALTEX. 2014;31(4):441-77
pubmed: 25027500
Cell Rep. 2019 Jun 25;27(13):3844-3859.e6
pubmed: 31242418
Stem Cell Reports. 2017 Jun 6;8(6):1516-1524
pubmed: 28528700
Sci Transl Med. 2017 Dec 20;9(421):
pubmed: 29263232
Mol Neurodegener. 2018 Dec 22;13(1):67
pubmed: 30577865
Acta Neuropathol Commun. 2020 May 29;8(1):74
pubmed: 32471486
Immunity. 2017 Sep 19;47(3):566-581.e9
pubmed: 28930663
Mol Neurodegener. 2017 Aug 2;12(1):56
pubmed: 28768545
Nat Genet. 2017 Sep;49(9):1373-1384
pubmed: 28714976
Nat Neurosci. 2020 Feb;23(2):194-208
pubmed: 31959936
Neuron. 2017 Apr 19;94(2):278-293.e9
pubmed: 28426964
Neuron. 2009 Oct 15;64(1):110-22
pubmed: 19840553
Nat Neurosci. 2014 Jan;17(1):131-43
pubmed: 24316888
J Clin Invest. 2020 Sep 1;130(9):4954-4968
pubmed: 32544086
BMC Bioinformatics. 2018 Dec 7;19(1):470
pubmed: 30526489
Science. 2010 Nov 5;330(6005):841-5
pubmed: 20966214
Neuron Glia Biol. 2006 May;2(2):125-138
pubmed: 16652167
Glia. 2016 Nov;64(11):1857-68
pubmed: 27442614
Nucleic Acids Res. 2015 Jul 1;43(W1):W566-70
pubmed: 25969447
Cell Rep. 2018 Jan 16;22(3):832-847
pubmed: 29346778
Front Cell Neurosci. 2018 Aug 06;12:242
pubmed: 30127723
Science. 2017 Jun 23;356(6344):
pubmed: 28546318
Neuron. 2020 Mar 4;105(5):837-854.e9
pubmed: 31902528
ALTEX. 2009;26(2):83-94
pubmed: 19565166
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
N Engl J Med. 2013 Jan 10;368(2):107-16
pubmed: 23150908
Glia. 2012 Jan;60(1):96-111
pubmed: 21989594
Neurodegener Dis. 2012;10(1-4):329-31
pubmed: 22301467
EMBO Mol Med. 2020 Apr 7;12(4):e11227
pubmed: 32154671
ALTEX. 2020 Mar 07;37(3):409-428
pubmed: 32150624
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Methods. 2008 Jul;5(7):621-8
pubmed: 18516045
N Engl J Med. 2013 Jan 10;368(2):117-27
pubmed: 23150934
Cell Rep. 2018 Aug 28;24(9):2300-2311
pubmed: 30157425
Cell Stem Cell. 2010 Oct 8;7(4):483-95
pubmed: 20887954
Nat Genet. 2019 Mar;51(3):414-430
pubmed: 30820047
Neuron. 2016 Jul 20;91(2):328-40
pubmed: 27477018
Sci Transl Med. 2014 Jul 2;6(243):243ra86
pubmed: 24990881
Nat Med. 2016 Nov;22(11):1358-1367
pubmed: 27668937
Cell. 2007 Nov 30;131(5):861-72
pubmed: 18035408
Cell Rep. 2020 Jun 30;31(13):107843
pubmed: 32610143
Nature. 2015 Feb 26;518(7540):547-51
pubmed: 25470051
Nat Neurosci. 2013 Mar;16(3):273-80
pubmed: 23334579
Nat Commun. 2019 Dec 20;10(1):5816
pubmed: 31862977
Acta Neuropathol Commun. 2017 Feb 17;5(1):16
pubmed: 28212663
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Mol Neurodegener. 2018 Sep 6;13(1):49
pubmed: 30185230
Mol Cell Biol. 2000 Jun;20(11):4106-14
pubmed: 10805752
FASEB J. 2020 Feb;34(2):2436-2450
pubmed: 31907987
Science. 2005 May 27;308(5726):1314-8
pubmed: 15831717
Nat Neurosci. 2012 Jul 26;15(8):1096-101
pubmed: 22837040
Nat Neurosci. 2006 Dec;9(12):1512-9
pubmed: 17115040
Neuron. 2012 May 24;74(4):691-705
pubmed: 22632727

Auteurs

Marvin Reich (M)

Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
In Vitro Toxicology and Biomedicine, Department inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Konstanz, Germany.

Iñaki Paris (I)

Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Achucarro Basque Center for Neuroscience, Science Park of the UPV/EHU, Leioa, Spain.

Martin Ebeling (M)

Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Nadine Dahm (N)

Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Christophe Schweitzer (C)

Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Dieter Reinhardt (D)

Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Roland Schmucki (R)

Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Megana Prasad (M)

Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Fabian Köchl (F)

Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Marcel Leist (M)

In Vitro Toxicology and Biomedicine, Department inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Konstanz, Germany.

Sally A Cowley (SA)

James Martin Stem Cell Facility, Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.

Jitao David Zhang (JD)

Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Christoph Patsch (C)

Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Simon Gutbier (S)

Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Markus Britschgi (M)

Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › Alzheimer's Risk Gene TREM2 Determines...
questionsmedicales.fr › Techniques d'investigation › Techniques in vitro › Techniques de culture › Techniques de culture cellulaire › Alzheimer's Risk Gene TREM2 Determines...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Différenciation cellulaire › Alzheimer's Risk Gene TREM2 Determines...
questionsmedicales.fr › Cellules › Cellules cultivées › Alzheimer's Risk Gene TREM2 Determines...
questionsmedicales.fr › Phénomènes génétiques › Génotype › Prédisposition génétique à une maladie › Alzheimer's Risk Gene TREM2 Determines...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Alzheimer's Risk Gene TREM2 Determines...
questionsmedicales.fr › Cellules › Cellules souches › Cellules souches pluripotentes › Cellules souches pluripotentes induites › Alzheimer's Risk Gene TREM2 Determines...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Glycoprotéines membranaires › Alzheimer's Risk Gene TREM2 Determines...
questionsmedicales.fr › Cellules › Névroglie › Microglie › Alzheimer's Risk Gene TREM2 Determines...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Alzheimer's Risk Gene TREM2 Determines...